Robert Gleavy

Is it time to #implement a marketing material review platform, like Veeva #PromoMats, within your life sciences organization? Here are 4 considerations that #marketing ops leaders should keep in mind to enable a compliant review process for promotional and non-promotional materials: https://hubs.ly/Q02wq1gK0

1

Is it time to #implement a marketing material review platform, like Veeva #PromoMats, within your life sciences organization? Here are 4 considerations that #marketing ops leaders should keep in mind to enable a compliant review process for promotional and non-promotional materials: https://hubs.ly/Q02Nqngk0

2

As therapies become increasingly personalized, biomarker data can provide essential insights throughout the pharmaceutical pipeline. Read our blog post to learn about the breadth and scope of use cases for this valuable data type https://hubs.ly/Q02DSrdX0

20

Creating a strong #MarketAccess strategy for your medical benefit drug can be tricky. MMIT's free ebook offers tips on ensuring a favorable status, keeping payer policies and clinical pathways aligned, and determining when contracting is needed. Download the ebook now to discover the five crucial steps your organization should take to establish a firm foundation for your commercialization journey: https://ow.ly/2n4450RIgnI. #MedicalBenefitTherapy #MedicalBenefitTherapies #CommercializationStrategy #HCPs

15

Les Enterline and industry peers weigh in for Contract Pharma's CRO industry report, an exploration of R&D trends and challenges and opportunities in today's market. Read on to learn what's driving growth in functional service partnerships: https://bit.ly/3VZHE5u

200

2 Comments

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences                       

9

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences        

7

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences

3

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences

7

Understanding HCRU and cost by care setting is one of HEOR teams’ greatest challenges. The lack of standardization across datasets, redacted payer info in claims, and missing data variables make it nearly impossible. That’s why our research data schema and cost imputation model (built on 4.4 billion healthcare claims) are so valuable. Learn more: https://lnkd.in/dGTUXFs3 #fda #pharmaceuticalindustry #pharmaceuticals #lifesciences 

1

In the evolving landscape of #ClinicalResearch, #HomeTrials are gaining prominence because of their patient-friendly approach. Read our blog to learn how partnering with a specialty #CRO can improve your study. https://bit.ly/3w8tncw

8

Explore the top reasons to choose a Salesforce-based CTMS for improved collaboration and real-time insights in clinical trials. https://hubs.li/Q02BbNCW0 To learn more book a meeting here: Connect at https://hubs.li/Q02BbSNB0 #CTMS #eTMF #EDC #RTSM #Safety #Biotechnology #Medicaldevices #diagnostics #Pharmaceutical #Cloudbyz #ClinicalTrials #Salesforce

2

With genuine transparency in pricing, contracts and claims processing, you will always know exactly what you are getting with PharmPix.

1

Did you know most payers have seen significant cost savings by switching to biosimilars, especially in treating conditions like rheumatoid arthritis, diabetes, and neutropenia? https://ow.ly/ZpKa30sI3hm Samantha Ngan from MMIT shares some fascinating insights about how payers embrace biosimilars, manage their use, and what providers expect in biosimilar growth. Check out the latest research at the link in this post.

11

Listen to Katrina Riggs, MSHS, CCRA, COO of Fast-Track Drugs & Biologics, LLC, share how her team has leveraged Zelta’s #ePRO capabilities and self-service support to accelerate #clinicaltrials with dozens of patient-reported outcomes, and how the platform has helped put their clients’ data management needs and drug development processes on the fast track. https://lnkd.in/eMTfH9_5

32

Great seeing everyone at PatientPoint® Upfront! Hart Mechlin, Veeva Systems, and a panel of industry experts discussed the data and analytics that matter most when assessing point-of-care campaign success. Let's continue the conversation: https://bit.ly/4dQxfjA #pharmamarketing #pharma #pharmaceuticals #digitalmarketing

31

As more pharma companies leverage AI, what are the most promising use cases? Hear from several industry leaders including COTA CEO Miruna Sasu in this article by Meagan Parrish from PharmaVoice. Miruna shares ways AI can improve our understanding of disease progression and outcomes throughout the patient journey. She notes how the increase of accessible genomic data plus accelerated data processing capabilities will allow us to take a more proactive approach to cancer care. #realworlddata #realworldevidence #pharma #healthcareAI #oncologyresearch https://lnkd.in/eBYA3NvY

21